Aliases & Classifications for Vulvar Disease

MalaCards integrated aliases for Vulvar Disease:

Name: Vulvar Disease 12 15
Vulvar Diseases 45 74
Vulvar Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:2059
MeSH 45 D014845
NCIt 51 C27631
SNOMED-CT 69 5089007
UMLS 74 C0042994

Summaries for Vulvar Disease

MedlinePlus : 44 The vulva is the external part of a woman's genitals. Some problems you can have with the vulvar area include Vaginitis or vulvovaginitis, swelling or infection of the vulva and vagina Skin problems due to allergy Vulvar cancer Vulvodynia, or vulvar pain Symptoms may include redness, itching, pain, or cracks in the skin. Treatment depends on the cause.

MalaCards based summary : Vulvar Disease, also known as vulvar diseases, is related to vulvar dystrophy and vulvitis, and has symptoms including pelvic pain and pruritus vulvae. An important gene associated with Vulvar Disease is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Acetylcholine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include lymph node, skin and cervix, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A female reproductive system diseaes that is located in the vulva.

Wikipedia : 77 A vulvar disease is a particular abnormal, pathological condition that affects part or all of the vulva.... more...

Related Diseases for Vulvar Disease

Diseases related to Vulvar Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Related Disease Score Top Affiliating Genes
1 vulvar dystrophy 31.8 CDKN2A LINC01191
2 vulvitis 31.6 KRT7 LINC01191
3 vulvar intraepithelial neoplasia 30.1 KRT7 TP53
4 in situ carcinoma 29.8 CDKN2A EGFR TP53
5 ulceration of vulva 11.0
6 atrophic vulva 11.0
7 cervix small cell carcinoma 10.5 CDKN2A TP53
8 cystic teratoma 10.4 KRT7 TP53
9 epithelial-myoepithelial carcinoma 10.4 KRT7 TP53
10 inverted transitional papilloma 10.4 CDKN2A KRT7
11 bladder squamous cell carcinoma 10.4 CDKN2A TP53
12 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
13 spitz nevus 10.4 CDKN2A TP53
14 malignant spiradenoma 10.4 KRT7 TP53
15 spiradenoma 10.4 KRT7 TP53
16 scrotal carcinoma 10.4 CDKN2A TP53
17 adenoid basal cell carcinoma 10.4 CDKN2A KRT7
18 bile duct adenoma 10.4 CDKN2A KRT7
19 endocervical carcinoma 10.4 CDKN2A KRT7
20 thyroid lymphoma 10.4 CDKN2A TP53
21 nasal cavity cancer 10.4 CDKN2A KRT7
22 bartholin's gland disease 10.4 CDKN2A TP53
23 anal squamous cell carcinoma 10.4 CDKN2A TP53
24 megaesophagus 10.4 CDKN2A TP53
25 gastric adenosquamous carcinoma 10.4 CDKN2A TP53
26 papillary serous adenocarcinoma 10.3 KRT7 TP53
27 anogenital venereal wart 10.3 CDKN2A TP53
28 anal canal carcinoma 10.3 CDKN2A KRT7
29 female reproductive endometrioid cancer 10.3 KRT7 TP53
30 horseshoe kidney 10.3 EGFR KRT7
31 renal pelvis transitional cell carcinoma 10.3 KRT7 UPK3A
32 non-invasive bladder papillary urothelial neoplasm 10.3 TP53 UPK3A
33 prostate squamous cell carcinoma 10.3 KRT7 TP53
34 meningeal melanomatosis 10.3 CDKN2A TP53
35 invasive bladder transitional cell carcinoma 10.3 TP53 UPK3A
36 glandular cystitis 10.3 KRT7 UPK3A
37 mucinous bronchioloalveolar adenocarcinoma 10.3 CDKN2A KRT7
38 brain ependymoma 10.3 EGFR TP53
39 malignant peritoneal mesothelioma 10.3 CDKN2A EGFR
40 peritoneal mesothelioma 10.3 CDKN2A EGFR
41 suppressor of tumorigenicity 3 10.3 CDKN2A TP53
42 well-differentiated liposarcoma 10.3 CDKN2A KRT7
43 anaplastic oligodendroglioma 10.3 CDKN2A EGFR
44 benign breast adenomyoepithelioma 10.3 EGFR KRT7
45 recurrent respiratory papillomatosis 10.3 EGFR TP53
46 breast papillomatosis 10.3 CCND1 CDKN2A
47 oncocytic breast carcinoma 10.3 EGFR KRT7
48 bladder carcinoma in situ 10.3 CDKN2A KRT7 TP53
49 nasal cavity adenocarcinoma 10.3 CDKN2A KRT7 TP53
50 glycogen-rich clear cell breast carcinoma 10.3 CDKN2A KRT7 TP53

Graphical network of the top 20 diseases related to Vulvar Disease:



Diseases related to Vulvar Disease

Symptoms & Phenotypes for Vulvar Disease

UMLS symptoms related to Vulvar Disease:


pelvic pain, pruritus vulvae

GenomeRNAi Phenotypes related to Vulvar Disease according to GeneCards Suite gene sharing:

27 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.7 KRT13
2 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.7 KRT13
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.7 EGFR
4 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.7 EGFR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.7 CCND1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.7 CCND1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.7 CCND1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.7 CCND1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.7 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.7 KRT13
11 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.7 EGFR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.7 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.7 CCND1 EGFR KRT13
14 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.7 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.7 EGFR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.7 CCND1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.7 KRT13
18 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.7 CCND1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.7 EGFR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.7 KRT13
21 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.7 KRT13
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.7 EGFR

Drugs & Therapeutics for Vulvar Disease

Drugs for Vulvar Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 223)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2 51-84-3 187
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 86386-73-4 3365
4
Clotrimazole Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 23593-75-1 2812
5
Dequalinium Approved, Investigational Phase 4 6707-58-0
6
Terconazole Approved Phase 4,Phase 3,Not Applicable 67915-31-5 441383
7
Petrolatum Approved, Investigational Phase 4,Phase 2,Not Applicable 8009-03-8
8
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
9
Tamoxifen Approved Phase 4 10540-29-1 2733526
10
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
11 abobotulinumtoxinA Phase 4,Phase 3,Phase 2
12 Acetylcholine Release Inhibitors Phase 4,Phase 3,Phase 2
13 Botulinum Toxins Phase 4,Phase 3,Phase 2
14 Cholinergic Agents Phase 4,Phase 3,Phase 2
15 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
21 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
26 Estrogens Phase 4,Phase 2,Not Applicable
27 Anti-Infective Agents, Local Phase 4,Phase 3
28 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Not Applicable
29 Estrogen Receptor Antagonists Phase 4
30 Aromatase Inhibitors Phase 4
31 Tea Phase 4
32 Estrogen Antagonists Phase 4
33
Amitriptyline Approved Phase 3 50-48-6 2160
34
Perphenazine Approved Phase 3 58-39-9 4748
35 Tomato Approved Phase 3
36
Nifedipine Approved Phase 3 21829-25-4 4485
37
Norepinephrine Approved Phase 3 51-41-2 439260
38
Levomilnacipran Approved, Investigational Phase 3 96847-54-0
39
Milnacipran Approved, Investigational Phase 3 92623-85-3 65833
40
Clindamycin Approved, Vet_approved Phase 3,Not Applicable 18323-44-9 29029
41
Butoconazole Approved Phase 3,Not Applicable 64872-76-0, 64872-77-1 47472
42
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
43
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
44
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 5280965 14956
45
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
46
Capsaicin Approved Phase 2, Phase 3,Phase 1 404-86-4 1548943
47
Clobetasol Approved, Experimental, Investigational Phase 3,Phase 2,Not Applicable 25122-46-7, 25122-41-2 5311051 32798
48
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
49
Calcium Approved, Nutraceutical Phase 3,Phase 2 7440-70-2 271
50 Antipsychotic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 241)
# Name Status NCT ID Phase Drugs
1 Botox on Vulvar Vestibulitis Unknown status NCT00119886 Phase 4 Botulinum toxin
2 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
3 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
4 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
5 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
6 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
7 Topical Treatment for Sexual Pain, Vulvar Pain, in Postmenopausal Women Not Taking Estrogens or Similiar Hormones. Women on Aromatase Inhibitors or Tamoxifen CAN Enter the Clinical Trial Recruiting NCT03682601 Phase 4 Sinecatechins Topical
8 Evaluation of Efficacy and Safety of Gynomax® XL Ovule Not yet recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
9 Physical Therapy as Adjuvant Treatment of Vulvodynia: a Randomized Controled Trial Unknown status NCT02871661 Phase 3 Amitriptyline
10 Dysbiosis in Localized Provoked Vulvodynia (LPV) Unknown status NCT02393911 Phase 3
11 Efficacy Study of Topical Application of Nifedipine Cream to Treat Vulvar Vestibulitis Completed NCT00496184 Phase 3 Nifedipine cream topical application
12 Savella in Treatment for Provoked Vestibulodynia Completed NCT01304589 Phase 3 Milnacipran
13 Vaginal Infection Study Completed NCT00616330 Phase 3 clindamycin phosphate/butoconazole nitrate;clindamycin phosphate;butoconazole nitrate
14 Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes Completed NCT00898352 Phase 3
15 Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage Completed NCT00224744 Phase 3
16 Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva Completed NCT00003325 Phase 3
17 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
18 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Completed NCT03158220 Phase 3
19 ProF-001_Phase IIa Completed NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
20 Therapy to Prevent Sexual Pain in Breast Cancer Survivors Completed NCT01539317 Phase 3 Topical liquid lidocaine;Topical saline
21 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
22 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
23 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
24 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
25 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
26 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
27 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
28 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
29 Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva Completed NCT00028951 Phase 3 fibrin sealant
30 A Pilot Study of the Effects of Botulinum Toxin in the Treatment of Provoked Vestibulodynia Recruiting NCT02858219 Phase 3 Botulinum Toxin Type A
31 A Study of the Effects of Topical Capsaicin in the Treatment of Provoked Vestibulodynia Recruiting NCT02854670 Phase 2, Phase 3 Capsaicin patch
32 Placebo-controlled RCT of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia Recruiting NCT02773641 Phase 3 Botulinum Toxin Type A;Sterile Saline Solution
33 Clobetasol Proprionate Versus Fractionated CO2 Laser for the Treatment of Lichen Sclerosus Recruiting NCT02573883 Phase 3 Clobetasol Propionate 0.05% ointment
34 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
35 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Recruiting NCT03734991 Phase 3 Ibrexafungerp;Placebo
36 A Study of Oral VT-1161 for the Treatment of Acute Vaginal Candidiasis (Yeast Infection) in Patients With Recurrent Vaginal Candidiasis Recruiting NCT03840616 Phase 3 VT-1161 150 mg capsule;Fluconazole 150 mg
37 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03562156 Phase 3 VT-1161;Placebo
38 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03561701 Phase 3 VT-1161;Placebo
39 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Recruiting NCT02997553 Phase 3 Indocyanine green;Technetium99
40 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Active, not recruiting NCT00943722 Phase 3
41 Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
42 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva Terminated NCT00006096 Phase 3 cisplatin
43 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
44 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Withdrawn NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
45 Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy Unknown status NCT01406769 Phase 2
46 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
47 Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis Completed NCT00004316 Phase 1, Phase 2 capsaicin
48 Infiltration of the Vestibulum Vaginae With Botulin Toxin in Patients With Localized Provoked Vulvodynia Completed NCT01747161 Phase 2 Botulin toxin;physiological water
49 Enoxaparin as Treatment for Vulvodynia Completed NCT00874484 Phase 2 Clexane (enoxaparin)
50 CC-10004 For The Treatment Of Vulvodynia Completed NCT00814632 Phase 2 CC-10004

Search NIH Clinical Center for Vulvar Disease

Cochrane evidence based reviews: vulvar diseases

Genetic Tests for Vulvar Disease

Anatomical Context for Vulvar Disease

MalaCards organs/tissues related to Vulvar Disease:

42
Lymph Node, Skin, Cervix, Testes, Brain, Colon, Tonsil

The Foundational Model of Anatomy Ontology organs/tissues related to Vulvar Disease:

20
The Vulva

Publications for Vulvar Disease

Articles related to Vulvar Disease:

(show top 50) (show all 68)
# Title Authors Year
1
Comparison of Serum Vitamin D Levels in Relation to Bowel and Bladder Symptoms in Women with Vulvar Diseases. ( 30747611 )
2019
2
"The Future of Vulvar Disease: New and Ongoing Challenges": Presidential Lecture - XXIV World Congress 2017, Mendoza, Argentina. ( 29474239 )
2018
3
Lichenoid vulvar disease: A review. ( 28492056 )
2017
4
Evaluation and Management of Vulvar Disease. ( 28778648 )
2017
5
HPV-related vulvar diseases and perspectives of p16INK4a immunochemistry: a review of the literature. ( 28574130 )
2017
6
Primary extramammary invasive Paget's vulvar disease: what is the standard, what are the challenges and what is the future for radiotherapy? ( 27473174 )
2016
7
What Do Patients Want? A Needs Assessment of Vulvodynia Patients Attending a Vulvar Diseases Clinic. ( 27484917 )
2016
8
Psychosexual Aspects of Vulvar Disease. ( 26125964 )
2015
9
Sexual well-being in patients with vulvar disease: results from a preliminary prospective matched case-control study. ( 26342683 )
2015
10
Lower Urinary Tract and Functional Bowel Symptoms in Women With Vulvar Diseases and Controls. ( 26052645 )
2015
11
Paediatric vulvar disease. ( 25134451 )
2014
12
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. ( 22454089 )
2012
13
Considerations for disease impact and outcome measures in vulvar disease. ( 22659774 )
2012
14
Prevalences of and risk factors for vulvar diseases in Nepal: a hospital-based study. ( 21244379 )
2011
15
The impact of the latest classification system of benign vulvar diseases on the management of women with chronic vulvar pruritus. ( 21508567 )
2011
16
Human papillomavirus infections and vulvar disease development. ( 19505910 )
2009
17
Vulvar diseases of the tropics: a review. ( 19301568 )
2009
18
Bladder and bowel symptoms among women with vulvar disease: are they universal? ( 18210896 )
2007
19
Vulvar disease pearls. ( 16677963 )
2006
20
Vulvar disease update. ( 17249297 )
2006
21
Vulvar disease: a pelvic floor pain disorder? ( 15970821 )
2005
22
Vulvar disease. ( 12100817 )
2002
23
The serious clinical problem of chronic vulvar disease. ( 12230080 )
2002
24
Vulvar disease in children: a clinical audit of 130 cases. ( 10720979 )
2000
25
Adverse behavioral and sexual factors in chronic vulvar disease. ( 10920305 )
2000
26
Dyspareunia and vulvar disease. ( 9839263 )
1998
27
Office gynecology for the primary care physician, part II: pelvic pain, vulvar disease, disorders of menstruation, premenstrual syndrome, and breast disease. ( 8614176 )
1996
28
Vulvar disease in the pediatric population. ( 8723821 )
1996
29
Clinicopathologic analysis of 370 cases of vulvar intraepithelial neoplasia. Italian Study Group on Vulvar Disease. ( 8887191 )
1996
30
Treatment of human papillomavirus-associated vulvar disease with the CO2-laser. Physical and histological aspects with use of a new scanning device, the SwiftLase. ( 8933926 )
1996
31
The commonest causes of symptomatic vulvar disease: a dermatologist's perspective. ( 8936065 )
1996
32
Proceedings of the 11th International Congress of the International Society for the Study of Vulvar Disease. Oxford, England, September 1991. ( 8095071 )
1993
33
International Society for the Study of Vulvar Disease. ( 8441124 )
1993
34
Advances in vulvar disease: lichen sclerosus et atrophicus et al. ( 1739579 )
1992
35
Vulvar diseases. ( 1606758 )
1992
36
General principles in the diagnosis and treatment of vulvar diseases. ( 1606759 )
1992
37
Ultrasonic surgical aspiration in the treatment of vulvar disease. ( 1876389 )
1991
38
Ultrasonic surgical aspiration in the treatment of vulvar disease. ( 2002980 )
1991
39
Proceedings of the 10th International Congress of the International Society for the Study of Vulvar Disease, Washington, D.C., October 1989. ( 1980515 )
1990
40
Proceedings of the Tenth World Congress of the International Society for the Study of Vulvar Disease, Washington, D.C., October 22-26, 1989. ( 1980928 )
1990
41
Superficial laser vulvectomy. IV. Extended laser vaporization and adjunctive 5-fluorouracil therapy of human papillomavirus-associated vulvar disease. ( 2166264 )
1990
42
Surgical-procedure terminology for the vulva and vagina. Report of an International Society for the Study of Vulvar Disease Task Force. ( 2277365 )
1990
43
The 1989 presidential address. International Society for the Study of Vulvar Disease. ( 2277371 )
1990
44
New nomenclature for vulvar disease. Report of the Committee on Terminology of the International Society for the Study of Vulvar Disease. ( 2352242 )
1990
45
A critique of current classifications of vulvar diseases. ( 2203271 )
1990
46
New nomenclature for vulvar disease: International Society for the Study of Vulvar Disease. ( 2707802 )
1989
47
Proceedings of the ninth world congress of the International Society for the Study of Vulvar Disease. Queensland, Australia, September 1987. ( 3172073 )
1988
48
International Society for the Study of Vulvar Disease--progress report. ( 3395571 )
1988
49
Proceedings of the Eighth World Congress of the International Society for the Study of Vulvar Disease. Mariehamn, Finland, September 9-15, 1985. ( 3772896 )
1986
50
Selected ISSVD (International Society for the Study of Vulvar Disease) abstracts. ( 3783540 )
1986

Variations for Vulvar Disease

Expression for Vulvar Disease

Search GEO for disease gene expression data for Vulvar Disease.

Pathways for Vulvar Disease

Pathways related to Vulvar Disease according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.6 CCND1 CDKN2A EGFR TP53
2 12.56 CCND1 CDKN2A EGFR TP53
3
Show member pathways
12.4 CCND1 CDKN2A EGFR TP53
4
Show member pathways
12.39 CCND1 CDKN2A EGFR TP53
5 12.03 CCND1 CDKN2A EGFR TP53
6 11.92 CCND1 EGFR TP53
7 11.89 CCND1 CDKN2A TP53
8 11.88 CCND1 EGFR TP53
9 11.77 CCND1 EGFR TP53
10 11.62 CCND1 EGFR TP53
11 11.56 CCND1 CDKN2A TP53
12 11.5 CCND1 CDKN2A EGFR TP53
13 10.96 CCND1 CDKN2A EGFR TP53
14 10.88 CCND1 CDKN2A EGFR TP53 UPK3A
15 10.82 CDKN2A TP53
16
Show member pathways
10.8 CDKN2A TP53

GO Terms for Vulvar Disease

Biological processes related to Vulvar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 9.26 CDKN2A TP53
2 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.16 EGFR TP53
3 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
4 response to UV-A GO:0070141 8.62 CCND1 EGFR

Molecular functions related to Vulvar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 8.92 CCND1 CDKN2A EGFR TP53

Sources for Vulvar Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....